FDA Safety Flags Regulator Overview
FDA · EMA · TGA · MHRA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

Peptide Therapy: A Regulator-Sourced Guide to What's Approved and What's Not

"Peptide therapy" is a broad marketing term used by clinics and online sellers for treatments that involve injectable or topical peptides. A small number of peptide medicines are FDA-approved for specific indications. The majority of products marketed under the "peptide therapy" label are not FDA-approved and lack controlled human safety data. This page summarises the regulator landscape.

Peptide therapy is a marketing term, not an FDA-approved category. A small number of peptide medicines (e.g. tesamorelin for HIV-lipodystrophy, GLP-1 agonists for diabetes and weight management, sermorelin under specific conditions, PT-141/Vyleesi for HSDD) are FDA-approved for narrow indications. Most clinic-marketed peptide therapies use compounded peptides that the FDA has flagged for significant safety risks.

Key Takeaways

  • Peptide therapy is a marketing term, not a regulator-defined treatment category.
  • A small set of peptide medicines are FDA-approved for specific indications: GLP-1 receptor agonists (T2DM, weight management), tesamorelin (HIV-lipodystrophy), bremelanotide (HSDD), sermorelin (limited prescription use), among others.
  • Most clinic-marketed peptide therapies (BPC-157, CJC-1295, TB-500, ipamorelin, AOD-9604) are not FDA-approved. The FDA has identified several of these for significant safety risks when compounded.
  • Common safety themes across unapproved peptide therapy: limited or no controlled human data, immunogenicity, impurities, unvalidated dosing, infection from non-sterile injection.

What is peptide therapy?

"Peptide therapy" is a marketing umbrella that clinics and online sellers use for treatments involving peptide molecules. Peptides are short chains of amino acids, usually 2–50 residues. Some are natural human hormones and signalling molecules; others are synthetic analogues or fragments. A small number have been characterised by regulators as safe and effective for specific medical indications. The majority of products in the "peptide therapy" market are not.

Which peptide medicines are FDA-approved?

FDA-approved peptide medicines include but are not limited to:

  • GLP-1 receptor agonists: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), exenatide (Byetta, Bydureon). Approved for type 2 diabetes, chronic weight management, and CV risk reduction in defined populations.
  • Tesamorelin (Egrifta): approved for HIV-associated abdominal lipodystrophy only.
  • Bremelanotide (PT-141, Vyleesi): approved for premenopausal hypoactive sexual desire disorder (HSDD).
  • Sermorelin: approved historically as a diagnostic agent and for paediatric growth hormone deficiency under specialist supervision.
  • Mecasermin (Increlex): approved for severe primary IGF-1 deficiency.
  • Various peptide hormones used in endocrine and reproductive medicine (insulin, glucagon, oxytocin, octreotide, leuprolide, etc.).

Which peptide therapies are not FDA-approved?

The most commonly marketed peptide-therapy products are not FDA-approved. The FDA has explicitly identified several as substances that may present significant safety risks when compounded:

  • BPC-157: not FDA-approved. FDA safety-risk listing.
  • CJC-1295 (with or without DAC): not FDA-approved. FDA safety-risk listing.
  • Ipamorelin acetate: not FDA-approved. FDA safety-risk listing.
  • AOD-9604: not FDA-approved. FDA safety-risk listing.
  • TB-500 (thymosin beta-4 fragment): not FDA-approved.
  • MK-677 (ibutamoren): not FDA-approved, heart-failure signal in trials.
  • Melanotan II: not approved anywhere; MHRA and TGA warnings.

Several Russian-developed peptides (Semax, Selank, Epitalon) are approved in the Russian Federation but not in the US, EU, or Australia.

What safety concerns are common across peptide therapy?

For peptides without FDA approval, the published literature and regulator statements identify a consistent set of concerns:

  • Absence or near-absence of controlled human safety data for the marketed use.
  • Immunogenicity (immune reactions to the peptide or impurities).
  • Inconsistent purity and potency in compounded or research-grade product.
  • Infection from non-sterile injection technique or contaminated material.
  • Drug interaction profile is largely uncharacterised, particularly for peptides affecting the GH/IGF-1 axis.
  • Long-term effects are not characterised by any regulator-reviewed dataset.

Check your full medication list in seconds

Allmeds scans the widest interaction database, so you can speak with your doctor with a clear picture.

Try it free → Talk to Sales

Common Questions

Is peptide therapy FDA approved?

Peptide therapy is a marketing term, not an FDA-defined treatment category. A small number of peptide medicines are FDA-approved for narrow indications (e.g. GLP-1 agonists for diabetes/obesity, tesamorelin for HIV-lipodystrophy, PT-141 for HSDD). Most clinic-marketed peptide therapies use peptides that the FDA has not approved.

What does the FDA say about peptide therapy?

The FDA has identified several commonly marketed peptides as substances that may present significant safety risks when compounded, including BPC-157, CJC-1295, ipamorelin acetate, and AOD-9604. The FDA position emphasises immunogenicity, peptide impurity, API characterisation complexity, and limited safety information.

Is peptide therapy safe?

Safety depends entirely on which peptide. Approved peptide medicines carry labelled risks that are characterised by regulator-reviewed trials. Unapproved peptides marketed as 'peptide therapy' lack controlled human safety data; common concerns include immunogenicity, impurities, and infection from non-sterile injection.

Which peptides are legal?

FDA-approved peptide medicines are legal when prescribed and dispensed through licensed pharmacies. Unapproved peptides may be sold for research use only and may not be legal for human therapeutic use depending on jurisdiction. See our peptide legal status page.

Should I tell my doctor I am considering peptide therapy?

Yes. Clinicians should know about any peptide use, especially before surgery, pregnancy, cancer treatment, or any change to prescription medicines. Peptide interactions with prescription medicines are largely uncharacterised.

References

  1. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
  2. Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.
  3. World Anti-Doping Agency. WADA Prohibited List. Source.
  4. European Medicines Agency. EPAR product information. Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice, diagnosis, or treatment. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.